These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 37490669)

  • 1. [An effect of antipsychotic and anticholinergic treatment on cognitive function in patients with schizophrenia].
    Tumova MA; Stepanova AA; Zazulina YS; Guseinova ZT; Zaitseva MM; Dyment IV; Kotsyubinsky AP; Ivanov MV
    Zh Nevrol Psikhiatr Im S S Korsakova; 2023; 123(7):80-85. PubMed ID: 37490669
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Prescribing patterns of antipsychotics in 13 French psychiatric hospitals].
    Bret P; Bret MC; Queuille E
    Encephale; 2009 Apr; 35(2):129-38. PubMed ID: 19393381
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antipsychotic medication versus psychological intervention versus a combination of both in adolescents with first-episode psychosis (MAPS): a multicentre, three-arm, randomised controlled pilot and feasibility study.
    Morrison AP; Pyle M; Maughan D; Johns L; Freeman D; Broome MR; Husain N; Fowler D; Hudson J; MacLennan G; Norrie J; Shiers D; Hollis C; James A;
    Lancet Psychiatry; 2020 Sep; 7(9):788-800. PubMed ID: 32649925
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of risperidone and quetiapine on cognition in patients with schizophrenia and predominantly negative symptoms.
    Riedel M; Spellmann I; Strassnig M; Douhet A; Dehning S; Opgen-Rhein M; Valdevit R; Engel RR; Kleindienst N; Müller N; Möller HJ
    Eur Arch Psychiatry Clin Neurosci; 2007 Sep; 257(6):360-70. PubMed ID: 17629731
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A randomized controlled trial of olanzapine versus haloperidol in the treatment of primary negative symptoms and neurocognitive deficits in schizophrenia.
    Lindenmayer JP; Khan A; Iskander A; Abad MT; Parker B
    J Clin Psychiatry; 2007 Mar; 68(3):368-79. PubMed ID: 17388705
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Determinants of first- and second-generation antipsychotic drug use in clinically unstable patients with schizophrenia treated in four European countries.
    Barbui C; Nosè M; Mazzi MA; Bindman J; Leese M; Schene A; Becker T; Angermeyer MC; Koeter M; Gray R; Tansella M
    Int Clin Psychopharmacol; 2006 Mar; 21(2):73-9. PubMed ID: 16421457
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antipsychotic drugs versus cognitive behavioural therapy versus a combination of both in people with psychosis: a randomised controlled pilot and feasibility study.
    Morrison AP; Law H; Carter L; Sellers R; Emsley R; Pyle M; French P; Shiers D; Yung AR; Murphy EK; Holden N; Steele A; Bowe SE; Palmier-Claus J; Brooks V; Byrne R; Davies L; Haddad PM
    Lancet Psychiatry; 2018 May; 5(5):411-423. PubMed ID: 29605187
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Augmentation of antipsychotics with glycine may ameliorate depressive and extrapyramidal symptoms in schizophrenic patients--a preliminary 10-week open-label study].
    Strzelecki D; Kropiwnicki P; Rabe-Jabłońska J
    Psychiatr Pol; 2013; 47(4):609-20. PubMed ID: 24946468
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prevalence of and Risk Factors for Extrapyramidal Side Effects of Antipsychotics: Results From the National FACE-SZ Cohort.
    Misdrahi D; Tessier A; Daubigney A; Meissner WG; Schurhoff F; Boyer L; Godin O; Bulzacka E; Aouizerate B; Andrianarisoa M; Berna F; Capdevielle D; Chereau-Boudet I; D'Amato T; Dubertret C; Dubreucq J; Faget-Agius C; Lançon C; Mallet J; Passerieux C; Rey R; Schandrin A; Urbach M; Vidailhet P; Llorca PM; Fond G;
    J Clin Psychiatry; 2019 Jan; 80(1):. PubMed ID: 30695288
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antipsychotics in the treatment of schizophrenia: an overview.
    Tandon R
    J Clin Psychiatry; 2011; 72 Suppl 1():4-8. PubMed ID: 22217436
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of tapering of long-term benzodiazepines on cognitive function in patients with schizophrenia receiving a second-generation antipsychotic.
    Kitajima R; Miyamoto S; Tenjin T; Ojima K; Ogino S; Miyake N; Fujiwara K; Funamoto Y; Arai J; Tsukahara S; Ito Y; Tadokoro M; Anai K; Kaneda Y; Yamaguchi N
    Prog Neuropsychopharmacol Biol Psychiatry; 2012 Mar; 36(2):300-6. PubMed ID: 22122880
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Oral antipsychotics for the treatment of schizophrenia: heterogeneity in efficacy and tolerability should drive decision-making.
    Volavka J; Citrome L
    Expert Opin Pharmacother; 2009 Aug; 10(12):1917-28. PubMed ID: 19558339
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dimensions of schizophrenia and their time course of response to a second generation antipsychotic olanzapine-A clinical study.
    Birur B; Thirthalli J; Janakiramaiah N; Shelton RC; Gangadhar BN
    Asian J Psychiatr; 2016 Dec; 24():17-22. PubMed ID: 27931900
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of Antipsychotic Dose Reduction in Late-Life Schizophrenia: A Prospective Dopamine D2/3 Receptor Occupancy Study.
    Graff-Guerrero A; Rajji TK; Mulsant BH; Nakajima S; Caravaggio F; Suzuki T; Uchida H; Gerretsen P; Mar W; Pollock BG; Mamo DC
    JAMA Psychiatry; 2015 Sep; 72(9):927-34. PubMed ID: 26131622
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Randomized controlled trial of the effect on Quality of Life of second- vs first-generation antipsychotic drugs in schizophrenia: Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1).
    Jones PB; Barnes TR; Davies L; Dunn G; Lloyd H; Hayhurst KP; Murray RM; Markwick A; Lewis SW
    Arch Gen Psychiatry; 2006 Oct; 63(10):1079-87. PubMed ID: 17015810
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [An effect of cholinesterase blockade on negative symptoms in schizophrenia].
    Morozova MA; Potanin SS; Rupchev GE; Burminskiy DS; Lepilkina TA; Beniashvili AG
    Zh Nevrol Psikhiatr Im S S Korsakova; 2021; 121(8):37-44. PubMed ID: 34481434
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Interest of a new instrument to assess cognition in schizophrenia: The Brief Assessment of Cognition in Schizophrenia (BACS)].
    Bralet MC; Navarre M; Eskenazi AM; Lucas-Ross M; Falissard B
    Encephale; 2008 Dec; 34(6):557-62. PubMed ID: 19081451
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Modafinil improves antipsychotic-induced parkinsonism but not excessive daytime sleepiness, psychiatric symptoms or cognition in schizophrenia and schizoaffective disorder: a randomized, double-blind, placebo-controlled study.
    Lohr JB; Liu L; Caligiuri MP; Kash TP; May TA; Murphy JD; Ancoli-Israel S
    Schizophr Res; 2013 Oct; 150(1):289-96. PubMed ID: 23938173
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prevalence of antipsychotic-induced extrapyramidal symptoms and their association with neurocognition and social cognition in outpatients with schizophrenia in the "real-life".
    Monteleone P; Cascino G; Monteleone AM; Rocca P; Rossi A; Bertolino A; Aguglia E; Amore M; Collantoni E; Corrivetti G; Cuomo A; Bellomo A; D'Ambrosio E; Dell'Osso L; Frascarelli M; Giordano GM; Giuliani L; Marchesi C; Montemagni C; Oldani L; Pinna F; Pompili M; Roncone R; Rossi R; Siracusano A; Vita A; Zeppegno P; Galderisi S; Maj M;
    Prog Neuropsychopharmacol Biol Psychiatry; 2021 Jul; 109():110250. PubMed ID: 33484755
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cognitive function and treatment response trajectories in first-episode schizophrenia: evidence from a prospective cohort study.
    Millgate E; Griffiths K; Egerton A; Kravariti E; Casetta C; Deakin B; Drake R; Howes OD; Kassoumeri L; Khan S; Lankshear S; Lees J; Lewis S; Mikulskaya E; Oloyede E; Owens R; Pollard R; Rich N; Smart S; Segev A; Verena Sendt K; MacCabe J;
    BMJ Open; 2022 Nov; 12(11):e062570. PubMed ID: 36410817
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.